168 related articles for article (PubMed ID: 24685815)
1. Targeted mouse complement inhibitor CR2-Crry protects against the development of atherosclerosis in mice.
Liu F; Wu L; Wu G; Wang C; Zhang L; Tomlinson S; Qin X
Atherosclerosis; 2014 May; 234(1):237-43. PubMed ID: 24685815
[TBL] [Abstract][Full Text] [Related]
2. Low-dose targeted complement inhibition protects against renal disease and other manifestations of autoimmune disease in MRL/lpr mice.
Atkinson C; Qiao F; Song H; Gilkeson GS; Tomlinson S
J Immunol; 2008 Jan; 180(2):1231-8. PubMed ID: 18178863
[TBL] [Abstract][Full Text] [Related]
3. Complement Inhibition Targeted to Injury Specific Neoepitopes Attenuates Atherogenesis in Mice.
Dai S; Liu F; Ren M; Qin Z; Rout N; Yang XF; Wang H; Tomlinson S; Qin X
Front Cardiovasc Med; 2021; 8():731315. PubMed ID: 34651027
[No Abstract] [Full Text] [Related]
4.
Lei B; Sleiman MM; Cheng Q; Tu Z; Zhu P; Goddard M; Martins PN; Langerude L; Nadig S; Tomlinson S; Atkinson C
Front Immunol; 2021; 12():630581. PubMed ID: 34394069
[TBL] [Abstract][Full Text] [Related]
5. A complement C3 inhibitor specifically targeted to sites of complement activation effectively ameliorates collagen-induced arthritis in DBA/1J mice.
Song H; Qiao F; Atkinson C; Holers VM; Tomlinson S
J Immunol; 2007 Dec; 179(11):7860-7. PubMed ID: 18025232
[TBL] [Abstract][Full Text] [Related]
6. Targeted Complement Inhibition Protects Vascularized Composite Allografts From Acute Graft Injury and Prolongs Graft Survival When Combined With Subtherapeutic Cyclosporine A Therapy.
Zhu P; Bailey SR; Lei B; Paulos CM; Atkinson C; Tomlinson S
Transplantation; 2017 Apr; 101(4):e75-e85. PubMed ID: 28045880
[TBL] [Abstract][Full Text] [Related]
7. Complement Inhibition Alleviates Cholestatic Liver Injury Through Mediating Macrophage Infiltration and Function in Mice.
Guo Z; Chen J; Zeng Y; Wang Z; Yao M; Tomlinson S; Chen B; Yuan G; He S
Front Immunol; 2021; 12():785287. PubMed ID: 35069557
[TBL] [Abstract][Full Text] [Related]
8. Deficiency of the complement regulatory protein CD59 accelerates the development of diabetes-induced atherosclerosis in mice.
Liu F; Sahoo R; Ge X; Wu L; Ghosh P; Qin X; Halperin JA
J Diabetes Complications; 2017 Feb; 31(2):311-317. PubMed ID: 27729184
[TBL] [Abstract][Full Text] [Related]
9. The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice.
Sekine H; Kinser TT; Qiao F; Martinez E; Paulling E; Ruiz P; Gilkeson GS; Tomlinson S
Arthritis Rheum; 2011 Apr; 63(4):1076-85. PubMed ID: 21452327
[TBL] [Abstract][Full Text] [Related]
10. A new treatment for neurogenic inflammation caused by EV71 with CR2-targeted complement inhibitor.
Qiu S; Liu N; Jia L; Yang G; Su W; Li J; Song L; Yang C; Wang J; Zhang C; Wang Z; Qiao F; Tomlinson S; Atkinson C; Sun Y; Huang L; Song H; Wang Y; Li Z
Virol J; 2012 Nov; 9():285. PubMed ID: 23173749
[TBL] [Abstract][Full Text] [Related]
11. New Insights on Complement Inhibitor CD59 in Mouse Laser-Induced Choroidal Neovascularization: Mislocalization After Injury and Targeted Delivery for Protein Replacement.
Schnabolk G; Beon MK; Tomlinson S; Rohrer B
J Ocul Pharmacol Ther; 2017 Jun; 33(5):400-411. PubMed ID: 28333572
[TBL] [Abstract][Full Text] [Related]
12. Dissecting the complement pathway in hepatic injury and regeneration with a novel protective strategy.
Marshall KM; He S; Zhong Z; Atkinson C; Tomlinson S
J Exp Med; 2014 Aug; 211(9):1793-805. PubMed ID: 25113972
[TBL] [Abstract][Full Text] [Related]
13. Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection.
Atkinson C; Song H; Lu B; Qiao F; Burns TA; Holers VM; Tsokos GC; Tomlinson S
J Clin Invest; 2005 Sep; 115(9):2444-53. PubMed ID: 16127466
[TBL] [Abstract][Full Text] [Related]
14. A new therapeutic strategy for lung tissue injury induced by influenza with CR2 targeting complement inhibitor.
Zhang C; Xu Y; Jia L; Yang Y; Wang Y; Sun Y; Huang L; Qiao F; Tomlinson S; Liu X; Zhou Y; Song H
Virol J; 2010 Feb; 7():30. PubMed ID: 20144216
[TBL] [Abstract][Full Text] [Related]
15. Complement regulator CD59 protects against atherosclerosis by restricting the formation of complement membrane attack complex.
Wu G; Hu W; Shahsafaei A; Song W; Dobarro M; Sukhova GK; Bronson RR; Shi GP; Rother RP; Halperin JA; Qin X
Circ Res; 2009 Feb; 104(4):550-8. PubMed ID: 19131645
[TBL] [Abstract][Full Text] [Related]
16. Identifying the Role of Complement in Triggering Neuroinflammation after Traumatic Brain Injury.
Alawieh A; Langley EF; Weber S; Adkins D; Tomlinson S
J Neurosci; 2018 Mar; 38(10):2519-2532. PubMed ID: 29437855
[TBL] [Abstract][Full Text] [Related]
17. A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury.
Huang Y; Qiao F; Atkinson C; Holers VM; Tomlinson S
J Immunol; 2008 Dec; 181(11):8068-76. PubMed ID: 19017999
[TBL] [Abstract][Full Text] [Related]
18. Crry, but not CD59 and DAF, is indispensable for murine erythrocyte protection in vivo from spontaneous complement attack.
Miwa T; Zhou L; Hilliard B; Molina H; Song WC
Blood; 2002 May; 99(10):3707-16. PubMed ID: 11986227
[TBL] [Abstract][Full Text] [Related]
19. Complement C3-Targeted Gene Therapy Restricts Onset and Progression of Neurodegeneration in Chronic Mouse Glaucoma.
Bosco A; Anderson SR; Breen KT; Romero CO; Steele MR; Chiodo VA; Boye SL; Hauswirth WW; Tomlinson S; Vetter ML
Mol Ther; 2018 Oct; 26(10):2379-2396. PubMed ID: 30217731
[TBL] [Abstract][Full Text] [Related]
20. Complement Component 5 (C5) Deficiency Improves Cognitive Outcome After Traumatic Brain Injury and Enhances Treatment Effects of Complement Inhibitors C1-Inh and CR2-Crry in a Mouse Model.
Chen M; Edwards SR; Maskey D; Woodruff TM; Tomlinson S; Reutens D
Neurotrauma Rep; 2023; 4(1):663-681. PubMed ID: 37908321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
